Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

  title={Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.},
  author={Anuhar Chaturvedi and Michelle Maria Araujo Cruz and Nidhi Jyotsana and Amritansh Sharma and Haiyang Yun and Kerstin G{\"o}rlich and Martin Wichmann and Adrian Schwarzer and Matthias Preller and Felicitas R Thol and Johann Meyer and Reinhard Haemmerle and Eduard Alexander Struys and Erwin E. W. Jansen and Ute Modlich and Zhixiong Li and Laura May Sly and Robert Geffers and Robert R. Lindner and Dietmar J Manstein and Ulrich Lehmann and J{\"u}rgen G E Krauter and Arnold Ganser and M. Heuser},
  volume={122 16},
Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequently found in glioma, acute myeloid leukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients. Mutant IDH produces 2-hydroxyglutarate (2HG), which induces histone- and DNA-hypermethylation through inhibition of epigenetic regulators. We investigated the role of mutant IDH1 using the mouse transplantation assay. Mutant IDH1 alone did not transform hematopoietic cells during 5 months of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 73 extracted citations

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2016
View 4 Excerpts
Highly Influenced

Imaging and Metabolism

Springer International Publishing • 2018
View 2 Excerpts


Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…